Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stock
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Discovery themes featuring this stock
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
3370.70 | 8,112 Cr | 19.63 | 9.43 | 3.49 | 42.11 | 52.41 | 25.64 | ||
569.15 | 7,075 Cr | 31.89 | 15.15 | 0.79 | 47.50 | 52.11 | 32.88 | ||
215.00 | 6,974 Cr | 4.49 | 5.21 | 0.00 | 116.01 | 80.89 | 71.55 | ||
845.50 | 6,799 Cr | 32.51 | 5.68 | 0.12 | 17.46 | 23.00 | 15.41 | ||
417.80 | 6,794 Cr | 24.14 | 2.73 | 1.20 | 11.32 | 15.18 | 9.64 | ||
1411.50 | 6,500 Cr | 56.34 | 6.96 | 0.00 | 12.36 | 14.43 | 7.58 | ||
685.65 | 6,217 Cr | 33.34 | 2.93 | 0.51 | 8.22 | 9.59 | 5.36 | ||
| Median: 7 Co. | — | 685.65 | 6,799 Cr | 31.89 | 5.68 | 0.51 | 17.46 | 23.00 | 15.41 |
Jeena Sikho Lifecare Ltd (JSLL) is currently trading at 555.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Jeena Sikho Lifecare Limited is an integrated Ayurvedic healthcare company operating a dual model of hospitals/clinics (services) and an OTC/personal care products business, running a hub‑and‑spoke network across 23 states with 58 hospitals, 59 clinics/day‑care centres and several thousand beds operational and in development. Q3 FY26 performance shows sharp operational momentum: Revenue at ₹221.7 crore (▲92% YoY, ▲17% QoQ), EBITDA ₹100.8 crore with a 45% margin and PAT ₹66.7 crore at a 30% margin, highlighting unusually high profitability for a healthcare chain driven by product margins and operating leverage in services. The company’s business model is capital‑light: management reports per‑bed set‑up costs of ₹3–4 lakh, 35/117 facilities run by franchisees, and a stated 71% 3‑year ROCE, enabling fast scalability while preserving a relatively robust balance sheet and low reported borrowings historically. Products and services are roughly parity contributors to recent revenue (about 49% services, 51% products for 9MFY26) with product gross margins near ~85%, providing strong cash generation that funds service expansion and supports rapid OTC rollouts via new distribution tie‑ups like Entero. Strategic growth levers include an international push (UAE, Kazakhstan, Nepal), a diagnostics partnership with Chandan, a planned Jeena Sikho Health Card for customer loyalty, and a target long‑term ambition of 7,000–10,000 beds alongside an accelerated OTC product roadmap.
Over the past 52 weeks, Jeena Sikho Lifecare Ltd has traded between a low of ₹491.95 and a high of ₹850.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Jeena Sikho Lifecare Ltd has a market capitalization of approximately 7,074.58. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Jeena Sikho Lifecare Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 31.89 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 7,074.58 Cr, Jeena Sikho Lifecare Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Jeena Sikho Lifecare Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Jeena Sikho Lifecare Ltd is 31.89. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Product/Operations Update
Jeena Sikho Lifecare Ltd launched four new Ayurvedic external pain-relief patches (Back 200 cm², Knee 220 cm², Pain Relief 50 cm² pack of 30, Large 75 cm² pack of 10) on 27-07-2026 for the domestic market.
Product/Operations Update
Jeena Sikho Lifecare Ltd launched four Ayurvedic external pain relief patches on 27 July 2026: Back Pain Relief Patch (200 cm²), Knee Pain Relief Patch (220 cm²), Pain Relief Patch (50 cm², pack of 30) and Large (75 cm², pack of 10).
Capex/Expansion
Jeena Sikho Lifecare Ltd will set up a new Client Support Centre at A-33, Sector-136, Noida (~17,700 sq.ft., ~300 seats). Investment ~₹2.37 Cr from internal accruals; expected operational within 45–60 days of lease execution.
Capex/Expansion
Jeena Sikho Lifecare Ltd will set up a new Client Support Centre at A-33, Sector-136 Noida (~17,700 sq.ft., ~300 seats). Estimated investment ~₹2.37 Crore from internal accruals; operational within 45-60 days of lease execution.
Capex/Expansion
Jeena Sikho Lifecare Ltd proposes a new Ayurvedic, Naturopathy & Panchkarma hospital at Kalyani, West Bengal (Plot B-11/114). ~13,000 sq ft, 60+ beds; operations estimated from Oct 2026; investment ~₹1.30 Crore via internal funds.
Capex/Expansion
Jeena Sikho Lifecare Ltd proposes a new Ayurvedic, Naturopathy & Panchkarma hospital at Kalyani, West Bengal: ~13,000 sq ft, 60+ beds, operations expected Oct 2026, estimated investment ~₹1.30 Cr funded from internal resources.
Jeena Sikho Lifecare Limited is an integrated Ayurvedic healthcare company operating a dual model of hospitals/clinics (services) and an OTC/personal care products business, running a hub‑and‑spoke network across 23 states with 58 hospitals, 59 clinics/day‑care centres and several thousand beds operational and in development.
Q3 FY26 performance shows sharp operational momentum: Revenue at ₹221.7 crore (▲92% YoY, ▲17% QoQ), EBITDA ₹100.8 crore with a 45% margin and PAT ₹66.7 crore at a 30% margin, highlighting unusually high profitability for a healthcare chain driven by product margins and operating leverage in services.
The company’s business model is capital‑light: management reports per‑bed set‑up costs of ₹3–4 lakh, 35/117 facilities run by franchisees, and a stated 71% 3‑year ROCE, enabling fast scalability while preserving a relatively robust balance sheet and low reported borrowings historically.
Products and services are roughly parity contributors to recent revenue (about 49% services, 51% products for 9MFY26) with product gross margins near ~85%, providing strong cash generation that funds service expansion and supports rapid OTC rollouts via new distribution tie‑ups like Entero.
Strategic growth levers include an international push (UAE, Kazakhstan, Nepal), a diagnostics partnership with Chandan, a planned Jeena Sikho Health Card for customer loyalty, and a target long‑term ambition of 7,000–10,000 beds alongside an accelerated OTC product roadmap.
Pharmaceuticals & Biotechnology
Pharmaceuticals
6,899 Cr
High Risk
31.1
37.2
1.2
15.2
850.00
491.95
Sales CAGR
Profit CAGR
ROE
ROCE
Bearish
5
Neutral
4
Bullish
5
Bearish
37
Neutral
4
Bullish
5
Bearish
32
Neutral
0
Bullish
0
